Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Broker tips: M&S, Mitchells & Butlers, AMS
(Sharecast News) - Citi downgraded its stance on Marks & Spencer on Thursday to 'neutral' from 'buy' and trimmed the price target to 170p from 175p. "Whilst we continue to view M&S's transformation positively, we also continue to expect the demand environment to deteriorate across 2023 and into 2024," the bank said.
"With a higher tax assumption driving a 5p TP target trim to 170p on 10x FYMar25E earnings per share and the shares up more than 10% since our March upgrade, we move to neutral with 4% upside/7% ETR."
Elsewhere, RBC Capital Markets initiated coverage of Advanced Medical Solutions with a 'sector perform' rating and 285p price target, as it sees a clear path to a re-rating but remains on the sidelines until then.
It said AMS is a well-run, cash generative business that is set to bolster its already impressive positioning in defensive end markets with a range of recent and upcoming launches.
"However, the current share price is already full, in our view, and our £2.85/share price target has insufficient implied upside for us to recommend buying the shares at this stage."
RBC said its sees "meaningful" upside potential from surgical sealant Seal-G, and may revisit its rating on positive clinical and commercial developments.
AMS develops and manufactures tissue-healing technology.
Analysts at Jefferies hiked their target price for shares of Mitchells & Butlers in light of the "robust" momentum in the pub owner's sales and given the prospect that cost pressures would abate.
Their estimates for its earnings before interest, taxes, depreciation and amortisation in 2023 and 2024 rose by 2% and 13%, respectively.
Earnings per share for those two years were seen coming in 10% and 55% higher.
All told, they boosted their target price from 170.0p to 270.0p and upgraded their recommendation from 'hold' to 'buy'.
They also highlighted the company's well-invested and well-located 80% freehold food-oriented pub estate.
All of those factors, they said, should help M&B win "material" market share even as other smaller operators struggle.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
